To report risk factors for ocular complications in adults with uveitis.
Methods:
Retrospective cohort study of 653 patients with uveitis (869 eyes) followed up for at least 1 month attended between May 1989 and December 2012.
Results:
After a median follow-up of 16 months (interquartile range = 3–59), 43.5% of patients developed one or more complications, including cataract formation (25%), iris alterations (20%), and macular edema (16%) as the most frequent. Older age, intermediate uveitis, chronic course, and uveitis activity >3 months were significantly more frequent among patients with complications. In the multivariate analysis, age ⩾65 years (hazard ratio = 2.76, 95% confidence interval = 1.72–4.4), chronic course (hazard ratio = 1.78, 95% confidence interval = 1.23–259), and uveitis activity >3 months (hazard ratio = 1.94, 95% confidence interval = 1.33–2.84) were predictors of complications.
Conclusion:
In the present series of patients with uveitis, advanced age, chronic uveitis, and inflammatory activity >12 weeks were risk factors for complications.
TsiroukiTDastiridouASymeonidisC, et al. A focus on the epidemiology of uveitis. Ocul Immunol Inflamm2016; 28: 1–15.
2.
RathinamSRNamperumalsamyP.Global variation and pattern changes in epidemiology of uveitis. Indian J Ophthalmol2007; 55(3): 173–183.
3.
de SmetMDTaylorSRBodaghiB, et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res2011; 30(6): 452–470.
4.
DandonaLDandonaRJohnRK, et al. Population based assessment of uveitis in an urban population in southern India. Br J Ophthalmol2000; 84(7): 706–709.
5.
AcharyaNRThamVMEsterbergE, et al. Incidence and prevalence of uveitis: results from the Pacific Ocular Inflammation Study. JAMA Ophthalmol2013; 131(11): 1405–1412.
6.
GritzDCWongIG.Incidence and prevalence of uveitis in Northern California; the Northern California Epidemi-ology of Uveitis Study. Ophthalmology2004; 111(3): 491–500.
7.
TranVTAuerCGuex-CrosierY, et al. Epidemiological characteristics of uveitis in Switzerland. Int Ophthalmol1994–1995; 18(5): 293–298.
8.
McCannelCAHollandGNHelmCJ, et al. Causes of uveitis in the general practice of ophthalmology. UCLA community-based uveitis study group. Am J Ophthalmol1996; 121(1): 35–46.
9.
LlopSMPapaliodisGN.Cataract surgery complications in uveitis patients: a review article. Semin Ophthalmol2017; 29: 1–6.
10.
GritzDCSchwaberEJWongIG.Complications of uveitis: the Northern California Epidemiology of Uveitis Study. Ocul Immunol Inflamm2017; 23: 1–11.
11.
de SmetMDOkadaAA. Cystoid macular edema in uveitis. Dev Ophthalmol2010; 47: 136–147.
12.
Barisani-AsenbauerTMacaSMMejdoubiL, et al. Uveitis—a rare disease often associated with systemic diseases and infections—a systematic review of 2619 patients. Orphanet J Rare Dis2012; 7: 57.
13.
GregoryACIIIKempenJHDanielE, et al. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the SITE Study. Ophthalmology2013; 120(1): 186–192.
14.
WoretaFThorneJEJabsDA, et al. Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol2007; 143(4): 647–655.
15.
LohARAcharyaNR.Incidence rates and risk factors for ocular complications and vision loss in HLA-B27-associated uveitis. Am J Ophthalmol2010; 150(4): 534–542.
16.
D’AmbrosioEMLa CavaMTortorellaP, et al. Clinical features and complications of the HLA-b27-associated acute anterior uveitis: a meta-analysis. Semin Ophthalmol2017; 32(6): 689–701.
17.
DickADTundiaNSorgR, et al. Risk of ocular complications in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology2016; 123(3): 655–662.
18.
Prieto-del-CuraMGonzález-GuijarroJ.Complications of uveitis: prevalence and risk factors in a series of 398 cases. Arch Soc Esp Oftalmol2009; 84: 523–528. (In Spanish)
19.
JabsDANussenblattRBRosenbaumJT.Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol2005; 140(3): 509–516.
20.
DeschenesJMurrayPIRaoNA, et al. International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul Immunol Inflamm2008; 16(1): 1–2.
21.
NussenblattRBPalestineAGChanCC, et al. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology1985; 92(4): 467–471.
22.
PatoEMartin-MartinezMACastelloA, et al. Devel-opment of an activity disease score in patients with uveitis (UVEDAI). Rheumatol Int2017; 37(4): 647–656.
23.
DennistonAKHollandGNKidessA, et al. Heterogeneity of primary outcome measures used in clinical trials of treatments for intermediate, posterior, and panuveitis. Orphanet J Rare Dis2015; 10: 97.
24.
ChylackLTJrWolfeJKSingerDM, et al. The lens opacities classification system III. The longitudinal study of cataract study group. Arch Ophthalmol1993; 111(6): 831–836.
25.
GroverSMurthyRKBrarVS, et al. Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (spectralis). Am J Ophthalmol2009; 148(2): 266–271.
26.
SenHNDryeLTGoldsteinDA, et al. Hypotony in patients with uveitis: the Multicenter Uveitis Steroid Treatment (MUST) trial. Ocul Immunol Inflamm2012; 20(2): 104–112.
27.
RothovaASuttorp-van SchultenMSFrits TreffersW, et al. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol1996; 80(4): 332–336.
28.
JonesNP.The Manchester Uveitis Clinic: the first 3000 patients, 2: uveitis manifestations, complications, medical and surgical management. Ocul Immunol Inflamm2015; 23(2): 127–134.
29.
LlorençVMesquidaMSainz de la MazaM, et al. Epidemiology of uveitis in a Western urban multiethnic population. The challenge of globalization. Acta Ophthalmol2015; 93(6): 561–567.
30.
NessTBoehringerDHeinzelmannS.Intermediate uveitis: pattern of etiology, complications, treatment and outcome in a tertiary academic center. Orphanet J Rare Dis2017; 12(1): 81.
NicholsonBPZhouMRostamizadehM, et al. Epidemiology of epiretinal membrane in a large cohort of patients with uveitis. Ophthalmology2014; 121(12): 2393–2398.
33.
AgrawalRMurthySGaneshSK, et al. Cataract surgery in uveitis. Int J Inflam2012; 2012: 548453.
34.
LevinMHPistilliMDanielE, et al. Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema. Ophthalmology2014; 121(2): 588–595.
35.
WeinerABenEzraD.Clinical patterns and associated conditions in chronic uveitis. Am J Ophthalmol1991; 112(2): 151–158.
36.
FardeauCChampionEMassambaN, et al. Uveitic macular edema. Eye2016; 30(10): 1277–1292.
37.
GroenFRamdasWde HoogJ, et al. Visual outcomes and ocular morbidity of patients with uveitis referred to a tertiary center during first year of follow-up. Eye2016; 30(3): 473–480.
38.
MainiRO’SullivanJReddyA, et al. The risk of complications of uveitis in a district hospital cohort. Br J Ophthalmol2004; 88(4): 512–517.
39.
McCluskeyPJTowlerHMLightmanS.Management of chronic uveitis. BMJ2000; 320(7234): 555–558.
40.
ArtornsombudhPPistilliMFosterCS, et al. Factors predictive of remission of new-onset anterior uveitis. Ophthalmology2014; 121(3): 778–784.
41.
SanchoLKramerMKoriatA, et al. Complications in intermediate uveitis: prevalence, time of onset, and effects on vision in short-term and long-term follow-up. Ocul Immunol Inflamm2019; 27(3): 447–455.
42.
BonfioliAADamicoFMCuriAL, et al. Review. Intermediate uveitis. Semin Ophthalmol2005; 20(3): 147–154.
43.
SacconiRGiuffrèCCorbelliE, et al. Emerging therapies in the management of macular edema: a review. F1000res2019; 8: 1413.
44.
TakahashiTOhtaniSMiyataK, et al. A clinical evaluation of uveitis-associated secondary glaucoma. Jpn J Ophthalmol2002; 46(5): 556–562.
45.
Muñoz-NegreteFJMoreno-MontañésJHernández-MartínezP, et al. Current approach in the diagnosis and management of uveitic glaucoma. Biomed Res Int2015; 2015: 742792.
46.
PerentesYVan TranTSickenbergM, et al. Subretinal neovascular membranes complicating uveitis: frequency, treatments, and visual outcome. Ocul Immunol Inflamm2005; 13(2–3): 219–224.
47.
D’AmbrosioETortorellaPIannettiL.Management of uveitis-related choroidal neovascularization: from the pathogenesis to the therapy. J Ophthalmol2014; 2014: 450428.
